VTYX

Ventyx Biosciences, Inc. VTYX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-22.83M

Quarter to Sep 30

Free cash flow

$-17.56M

Quarter to Sep 30

Top Institutional Holders

as of Q1 2026
$21.0K total
IFP Advisors, Inc
$21.0KNew
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

ROIC

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VTYX

Earnings Per Share

13fpro.ai/company/VTYX

Loading ratio trend…

VTYX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Ventyx Biosciences, Inc. (VTYX): stock profile, AI score and financials

Ventyx Biosciences, Inc. (VTYX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VTYX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2025), Ventyx Biosciences, Inc. reports net income of $-22.8M, free cash flow of $-17.6M. VTYX trades on the Nasdaq exchange and files with the SEC under CIK 1851194. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ventyx Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1851194 →